Literature DB >> 1323653

Differential regulation of subtypes m1-m5 of muscarinic receptors in forebrain by chronic atropine administration.

S J Wall1, R P Yasuda, M Li, W Ciesla, B B Wolfe.   

Abstract

The regulation of individual muscarinic receptor subtypes in rat cerebral cortex/dorsal hippocampus was examined following 14-day administration of the nonselective antagonist atropine. Total muscarinic receptor density increased 24%, from 2196 fmol/mg to 2722 fmol/mg. The nature of this increase was examined using a panel of antisera selective for the m1 to m5 muscarinic receptors. Thus, 97% of all cortical/hippocampal receptors were accounted for by immunoprecipitation. Three subtypes were observed to increase significantly in density: m1 receptor from 824 to 982 fmol/mg (19%, P less than .05); m2 receptor from 476 to 519 fmol/mg (9%, N.S.); m3 receptor from 259 to 438 fmol/mg (69%, P less than .001); m4 receptor from 574 to 638 fmol/mg (11%, P less than .05); and the m5 receptor from 23 to 38 fmol/mg (65%, N.S.). Receptors coupled to the hydrolysis of phosphoinositides (m1, m3, m5) appeared to be preferentially up-regulated (32% over control levels, P less than .001) compared with those coupled to the inhibition of adenylyl cyclase (m2, m4; 10% over control levels, P less than .05). The absolute density of the molecularly defined m1 and m4 receptors, which reportedly possess the highest affinity for pirenzepine (M1), increased 16% (P less than .05), whereas the density of receptors having the lowest affinity for pirenzepine (m2, m3 and m5) increased 31% (P less than .001) with atropine treatment. When the increase in total receptor density was examined with [3H]pirenzepine, the 16% elevation in high-affinity (m1 and m4) sites was not detected.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1323653

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Muscarinic receptor subtype-3 gene ablation and scopolamine butylbromide treatment attenuate small intestinal neoplasia in Apcmin/+ mice.

Authors:  Jean-Pierre Raufman; Jasleen Shant; Guofeng Xie; Kunrong Cheng; Xue-Min Gao; Brian Shiu; Nirish Shah; Cinthia B Drachenberg; Jonathon Heath; Jürgen Wess; Sandeep Khurana
Journal:  Carcinogenesis       Date:  2011-06-24       Impact factor: 4.944

2.  Synaptic muscarinic response types in hippocampal CA1 interneurons depend on different levels of presynaptic activity and different muscarinic receptor subtypes.

Authors:  L Andrew Bell; Karen A Bell; A Rory McQuiston
Journal:  Neuropharmacology       Date:  2013-06-05       Impact factor: 5.250

3.  The effect of hyperphenylalaninaemia on the muscarinic acetylcholine receptor in the HPH-5 mouse brain.

Authors:  F A Hommes
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

4.  Molecular mechanisms of muscarinic receptors in mouse scleral fibroblasts: Prior to and after induction of experimental myopia with atropine treatment.

Authors:  V A Barathi; Roger W Beuerman
Journal:  Mol Vis       Date:  2011-03-09       Impact factor: 2.367

Review 5.  Modulation of Hippocampal Circuits by Muscarinic and Nicotinic Receptors.

Authors:  Holger Dannenberg; Kimberly Young; Michael Hasselmo
Journal:  Front Neural Circuits       Date:  2017-12-13       Impact factor: 3.492

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.